Shattuck Labs Inc. specializes in the development of biologic medicines, particularly focusing on tumor necrosis factor (TNF) receptor modulators. Their lead program, SL-325, is a monoclonal antibody antagonist targeting Death Receptor 3 (DR3), which is designed to provide a more effective blockade of the TL1A/DR3 signaling pathway. This innovative approach aims to address significant unmet medical needs in treating inflammatory bowel disease (IBD) and other inflammatory autoimmune diseases. The company leverages advanced protein engineering techniques to enhance the specificity and efficacy of their therapeutic candidates, which include both monospecific and bispecific antibodies.

In addition to SL-325, Shattuck Labs is developing other therapeutic candidates, such as SL-425, which features an extended half-life and targets the same DR3 receptor for IBD treatment. Their pipeline reflects a commitment to creating specialized therapeutics that can either activate or inhibit TNF receptors, thereby addressing various oncology and autoimmune/inflammatory conditions. The company emphasizes a collaborative approach, bringing together experts from diverse fields to challenge conventional methodologies and drive the development of transformative medicines that significantly improve patient outcomes.

United States

At Shattuck Labs, we are pioneering a new class of dual function fusion proteins to create novel therapeutics for patients with cancer and autoimmune disease.

Cancer

Hematologic Diseases

Urogenital Diseases

Shattuck Labs Inc

Inflammatory bowel disease

SL-325 is a potential first-in-class Death Receptor 3 (DR3) blocking antibody designed to achieve a complete and durable blockade of the clinically validated DR3/TL1A pathway. Shattuck’s preclinical studies demonstrate high affinity binding and superior activity over TL1A antibodies, and offer a data-driven rationale for targeting the TNF receptor, DR3, versus its ligand, TL1A.

SL-325

Lymphoma

Solid tumor/s

SL-279252 is a bi-functional fusion protein that contains the extracellular domain (ECD) of PD1 linked to the ECD of OX40L through an IgG4 Fc linker protein. Proper folding of the OX40L side of the ARC leads to a trimer of OX40L molecules, which, when bound to OX40, potently stimulates an activation pathway in immune cells.
The ARC molecule consists of PD1 linked to OX40L through an Fc linker protein and binds to PDL1 on tumor cells and OX40 on T cells. This results in the blockade of PD1 signaling in T cells while simultaneously activating the OX40 activation pathway, leading to activated T cells in the tumor microenvironment.

SL-279252

Ovarian cancer

SL-172154 is a bi-functional fusion protein that targets CD47 on malignant cells and CD40 on immune cells (antigen presenting cells).
The ARC consists of Sirpα linked to CD40L, providing checkpoint blockade (CD47 axis) and potent costimulation (CD40 axis). CD47 is upregulated in essentially every cancer type to inhibit innate immune cells from phagocytosing (eating) the tumor cells. By blocking this signal though Sirpα binding, the surface of the tumor cells are coated with the ARC, allowing the CD40L side to bind to CD40 on antigen presenting cells (APCs), which will lead to enhanced antigen presentation to CD8+ and CD4+ T lymphocytes and tumor cell phagocytosis by the APC cell.

SL-172154

Cutaneous squamous cell carcinoma

Head and neck squamous cell carcinoma

Acute myeloid leukemia

Myelodysplastic syndrome

SL-172154 +/- azacitidine

SL-172154 is a bi-functional fusion protein that targets CD47 on malignant cells and CD40 on immune cells (antigen presenting cells).
The ARC consists of Sirpα linked to CD40L, providing checkpoint blockade (CD47 axis) and potent costimulation (CD40 axis). CD47 is upregulated in essentially every cancer type to inhibit innate immune cells from phagocytosing (eating) the tumor cells. By blocking this signal though Sirpα binding, the surface of the tumor cells are coated with the ARC, allowing the CD40L side to bind to CD40 on antigen presenting cells (APCs), which will lead to enhanced antigen presentation to CD8+ and CD4+ T lymphocytes and tumor cell phagocytosis by the APC cell.
&nbsp;(SIRPα-Fc-CD40L)

Shattuck Labs Inc

Company Details